Serogroup b meningococcal disease outbreak and carriage evaluation at a college — rhode island, 2015

Morbidity and Mortality Weekly Report

Volumn 64, Issue 22, 2015, Pages 606-607

  Soeters, Heidi M ^a,b   McNamara, Lucy A ^a,b   Whaley, Melissa ^b   Wang, Xin ^b   Alexander Scott, Nicole ^c   Kanadanian, Koren V ^d   Kelleher, Catherine M ^d   Macneil, Jessica ^b   Martin, Stacey W ^b   Raines, Nathan ^e   Sears, Steven ^d   Vanner, Cynthia ^c   Vuong, Jeni ^b   Bandy, Utpala ^c   Sicard, Kenneth ^d   Patel, Manisha ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c RHODE ISLAND DEPARTMENT OF HEALTH   (United States)

^d PROVIDENCE COLLEGE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; MENINGOCOCCUS VACCINE;

ADOLESCENT; CASE REPORT; DISEASE OUTBREAKS; FEMALE; HETEROZYGOTE; HUMAN; INCIDENCE; ISOLATION AND PURIFICATION; MALE; MASS IMMUNIZATION; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; NEISSERIA MENINGITIDIS; UNITED STATES; UNIVERSITY; YOUNG ADULT;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CARRIER STATE; CIPROFLOXACIN; DISEASE OUTBREAKS; FEMALE; HUMANS; INCIDENCE; MALE; MASS VACCINATION; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; RHODE ISLAND; UNIVERSITIES; YOUNG ADULT;

EID: 84931087266     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics 2015;135:798–804.
2. MacNeil J. Considerations for use of serogroup B meningococcal (MenB) vaccines in persons at increased risk. Advisory Committee on Immunization Practices; February 25, 2015; Atlanta, GA. Available at http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-02/ mening-MacNeil.pdf.
3. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(No. RR-2).
4. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015;64:608–12.
5. CDC. Interim guidance for control of serogroup B meningococcal disease outbreaks in organizational settings. Available at http://www.cdc.gov/meningococcal/downloads/interim-guidance.pdf.
6. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011;29:4739–44.
7. Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010;28:6086–93.
8. Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384:2123–31.
9. Wu HM, Harcourt BH, Hatcher C P, et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 2009;360:886–92.
10. 10. Weiss D, Stern EJ, Zimmerman C, et al.; New York City Meningococcal Investigation Team. Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York. Clin Infect Dis 2009;48:894–901.